These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12244784)

  • 1. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J; Tovar I; Martínez P
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract]   [Full Text] [Related]  

  • 2. [Merger of bone biology and immunology].
    Suda T; Shima N; Higashio K
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract]   [Full Text] [Related]  

  • 3. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S; Hata T
    Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular mechanism of bone metabolism].
    Kotake S; Utagawa N; Suda T; Kamatani N
    Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC; Heufelder AE; Erben RG
    J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L; Schwarz EM; Boyce BF
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advance in basic research for osteoporosis].
    Suda T; Miyaura C
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
    [No Abstract]   [Full Text] [Related]  

  • 13. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC; Crotti TN; Goldring SR; Gravallese EM
    Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
    Hofbauer LC
    Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases.
    Siggelkow H; Eidner T; Lehmann G; Viereck V; Raddatz D; Munzel U; Hein G; Hüfner M
    J Bone Miner Res; 2003 Mar; 18(3):529-38. PubMed ID: 12619938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone cancer pain and the role of RANKL/OPG.
    Clohisy DR; Mantyh PW
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):293-300. PubMed ID: 15615497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
    Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.